AbbVie posts IMGN632 BPDCN results; opens NOA LIFT filler trial vs VOLIFT

AbbVie had an active week across oncology and aesthetics, with one long-running trial posting results and one new filler study beginning recruitment.

• IMGN632, a CD123-targeted antibody drug conjugate, has results posted from its Phase 1/2 study in CD123-positive AML, ALL, and BPDCN (NCT03386513). The study was designed to determine the maximum tolerated dose and assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-leukemia activity of IMGN632 monotherapy in patients with CD123-positive disease.¹ Enrollment reached 179 participants.¹
• NOA LIFT, a hyaluronic acid filler, is now recruiting in a Phase 3 study comparing it to JUVÉDERM VOLIFT with Lidocaine for correction of nasolabial folds (NCT07794878). Around 288 adult participants with moderate to severe nasolabial folds will be enrolled at multiple sites in China.² The primary outcome is responder status based on live assessment using the Nasolabial Fold Severity Scale.²
• A Phase 4 study combining BOTOX Cosmetic and JUVÉDERM products (SKINVIVE, VOLUX, VOLUMA) for jawline and neck treatment has not yet opened recruitment (NCT07794891), with an estimated start of September 2026. The goal of the study is to evaluate overall participant satisfaction with the jawline and neck, using select Juvéderm products and onabotulinumtoxinA in the jaw area and neck.³ Enrollment is estimated at 100 participants.³
• JUVÉDERM VOLITE XC, an HA gel implant for neck lines, completed its Phase 3 study with results posted (NCT05316233). Enrollment reached 159 participants.⁴ The primary outcome measured the percentage of participants achieving responder status on the Allergan Transverse Neck Lines Scale, a 5-point scale where a responder shows at least a 1-grade improvement.⁴